The Wall Street Journal: Sanofi said to be near $11.5 billion deal to buy Bioverativ

Sanofi SA SNY, +0.20% is nearing a deal to buy hemophilia drugmaker Bioverativ Inc. for more than $11.5 billion as the French drugmaker looks set to clinch a big deal while it braces for generic competition for its top-selling product.

A deal, which could be announced as soon as Monday, would value the former Biogen Inc. unit at $105 a share, according to people familiar with the matter. The price would represent a 63% premium to where Bioverativ BIVV, +2.17% closed trading Friday. It is possible the talks could fall apart before a deal is reached.

An expanded version of this report appears on WSJ.com.

>>> Original Source <<<